Next Best Action (NBA) has become the dominant initiative across commercial life sciences for a straightforward reason: the alternative stopped working. Campaign-level targeting, segment-level messaging, and call plans built from a quarterly review cycle are a poor fit for an environment where healthcare professional (HCP) access is declining, channel complexity is rising, and the data to do better already exists inside most commercial operations.
According to Deloitte, NBA is now a the top strategic focus across their entire life sciences client base. That doesn’t, however, mean most companies are doing it well. Most are not. The gap between a well-functioning NBA program and a struggling one rarely comes down to the technology alone. It comes down to whether teams understand what they are actually building, where it breaks, and how to get field reps to use it.
This post covers all three.
What is Next Best Action in Pharma?
Next Best Action is a data-driven decision-support model that evaluates the full range of possible actions for each individual HCP and surfaces the single most effective one, through the right channel, at the right moment.
The word to focus on is individual. Traditional pharma marketing builds a proposition and then looks for a suitable audience. NBA reverses that. It starts with a specific HCP, takes in everything known about them, and works backward to determine what engagement is most likely to move them.
An NBA engine processes signals from multiple sources at once: prescribing history, CRM activity, digital engagement, rep interactions, third-party data, formulary status. It identifies patterns across that data that no human could track across a full territory and produces a recommendation. Call this HCP today. Send this asset. Reference this data point. Use this channel.
What data does NBA draw on?
The most common inputs in pharma:
- Prescribing and claims data, used compliantly to understand HCP behavior and volume
- CRM records, including past interactions, call notes, and sentiment from field reps
- Digital engagement, including email opens, website visits, event attendance, and content downloads
- Third-party data on specialty, practice size, patient population, and channel preference
- Market access and formulary status, showing which payers cover which products for which HCPs
- HCP affinity and propensity signals, behavioural indicators of likely responsiveness to specific messaging
The engine synthesises these inputs, surfaces patterns, and produces a recommendation a rep can act on in seconds, or that a system can execute through a digital channel without rep involvement at all.
Why are commercial teams adopting NBA now?
Three pressures are converging, and NBA addresses all three.
1. HCP access is declining
The share of physicians willing to see pharma reps in person has been falling for years and has not recovered. Field teams are covering larger territories with fewer face-to-face opportunities. That makes every interaction more consequential. NBA helps teams decide which interactions to prioritize and what to say when they get them.
2. Channels have multiplied
An HCP can now be reached through field, digital, remote, AI tools, and peer-to-peer channels, often all in the same week. Without coordination, a rep’s call, a brand email, an MSL’s scientific exchange, and a programmatic ad can reach the same HCP with conflicting messages from the same company. NBA is what engineers the coordination rather than hoping for it.
3. The data is there but not being used
Most commercial operations already have CRM systems, claims data subscriptions, digital engagement platforms, and third-party data partnerships. That is a significant amount of information sitting largely unused. NBA is what turns it into a specific action. Without it, the data costs money. With it, every rep interaction and every digital touchpoint is informed by the full picture.
The outcome, when NBA is properly built and adopted, is measurable. Field teams focus time on HCPs who are movable right now, not on working through a static call list. Digital channels reach the right people with the right message. And prescription lift follows from better quality engagement, not simply more of it.
Why are commercial teams adopting NBA now?
Three pressures are converging, and NBA addresses all three.
1. HCP access is declining
The share of physicians willing to see pharma reps in person has been falling for years and has not recovered. Field teams are covering larger territories with fewer face-to-face opportunities. That makes every interaction more consequential. NBA helps teams decide which interactions to prioritize and what to say when they get them.
2. Channels have multiplied
An HCP can now be reached through field, digital, remote, AI tools, and peer-to-peer channels, often all in the same week. Without coordination, a rep’s call, a brand email, an MSL’s scientific exchange, and a programmatic ad can reach the same HCP with conflicting messages from the same company. NBA is what engineers the coordination rather than hoping for it.
3. The data is there but not being used
Most commercial operations already have CRM systems, claims data subscriptions, digital engagement platforms, and third-party data partnerships. That is a significant amount of information sitting largely unused. NBA is what turns it into a specific action. Without it, the data costs money. With it, every rep interaction and every digital touchpoint is informed by the full picture.
The outcome, when NBA is properly built and adopted, is measurable. Field teams focus time on HCPs who are movable right now, not on working through a static call list. Digital channels reach the right people with the right message. And prescription lift follows from better quality engagement, not simply more of it.
Five ways pharma teams use NBA to drive prescription lift
The commercial applications of next best action marketing are broader than most teams expect when they start.
1. Prioritizing field rep time across a territory
Not every HCP in a territory is equally worth pursuing at the same moment. NBA engines re-score HCPs based on current signals, including prescribing trends, recent engagement, access windows, diagnostic or lab signals, and competitive activity, and surface the day’s highest-priority targets for each rep. Rather than working from a call plan built at the start of a quarter, reps work from a list that reflects what is happening now. More time goes to HCPs who are ready to move. Less time goes to calls that are unlikely to change anything.
2. Coordinating brand and field around a single HCP journey
One of the more expensive failures in pharma commercial execution is when field and brand teams work in parallel rather than together. A rep calls an HCP on Monday. The brand team sends an email on Tuesday that contradicts the Monday message. A digital ad fires on Wednesday that drops the HCP into a different campaign entirely. None of these teams intended to create confusion. They simply had no visibility into what the others were doing.
NBA addresses this at the orchestration layer. When a recommendation engine has sight across field, brand, and digital activity, it can sequence them into a coherent journey, with each touchpoint built on the last rather than working against it.
3. Personalizing digital engagement at scale
Digital channels give pharma brands reach that field teams cannot match. An HCP who is not accessible for a rep call can still be reached via email, digital media, or peer-to-peer platforms. But digital personalization in pharma has historically been blunt. The same email goes to a segment of two thousand HCPs, differentiated only by specialty or prescribing history.
NBA enables one-to-one personalization at scale. The content an HCP receives digitally, the article, the clinical resource, the data point, the call-to-action, is selected based on that specific HCP’s signals, not their segment membership. That is what moves digital from broadcast to something closer to dialogue.
4. Supporting launches with signal-driven targeting
During a new indication or product launch, the window of maximum influence is narrow. HCPs form prescribing habits early. Reaching the right HCPs before those habits are established is often the difference between a launch that builds momentum and one that plateaus.
NBA is well suited to launch contexts because it processes early prescribing signals and channel response data as they come in. Teams can identify which HCPs are responding to which engagement types and adjust within the launch window, not after a quarterly review when the moment has long since passed.
5. Measuring and adjusting as you go
Most pharma marketing programs are evaluated at set intervals. NBA is designed to be evaluated constantly, because the recommendations are updated based on what is and is not working.
When a rep acts on a recommendation and the HCP responds, that feeds back into the model. When they do not, that feeds back too. Over time the system learns which recommendations produce results in which contexts. That learning is what separates NBA from a reporting tool. A reporting tool tells you what happened. NBA changes what happens next.
Where Next Best Action breaks down
Most NBA programs that are not delivering what they should are not failing because the technology does not work. Two problems are responsible for most of the underperformance, and both are predictable.
Too many recommendations
An NBA engine has access to a wide range of signals and can generate a long list of possible actions for any given HCP. When that list arrives in a rep’s CRM interface ranked from one to thirty, most reps ignore it and go back to doing what they were already doing. The problem is not the algorithm. It is the presentation.
The recommendation layer needs to be configured to surface one clear action per HCP per day, not a ranked list. Call this HCP. Use this message. Via this channel. That is something a rep can act on. A list of possibilities, however well-ranked, is not.
Â
The last-mile gap
NBA generates a recommendation. The recommendation travels through a system. It appears in a CRM interface. And then it depends entirely on a field rep or an automated trigger to act on it at the right moment.
The most common failure point is timing. A recommendation to schedule a call appears two days after the rep has already visited the HCP. An email trigger fires while the HCP is receiving three other brand communications in the same week. The recommendation was correct based on the data. It arrived too late to matter. And many systems can’t reprioritize or reschedule that action effectively to improve that HCP’s journey.
Closing this gap takes two things. First, integration between the NBA engine and the execution channels, so recommendations can trigger actions automatically where field involvement is not needed. Second, configuration of the timing and frequency rules that govern when recommendations are delivered, so they arrive when they can still be acted on.
Adoption Is the problem nobody budgets for
Field technology adoption in pharma is one of the most underestimated challenges in commercial operations. A field rep has been doing their job for years. They have relationships, instincts, and a rhythm that works for them. Asking them to trust an AI recommendation over their own judgement, and to change their daily workflow to act on it, is not a change management problem, not a technology problem. Most NBA implementations don’t budget for it.
The programs that achieve strong and lasting adoption tend to share a few things.
Show the reasoning, not just the result
Reps act on recommendations they understand. When the interface shows not just the recommendation but why it was generated, this HCP has had three digital touchpoints in the past month but no field contact in six weeks, their prescribing volume in this indication has increased, your message on the new formulation is resonating with similar HCPs in this market, the rep can evaluate it, trust it, and act on it with confidence. A black-box instruction from a system they did not ask for gets ignored.
Put it where reps already work
If reps need to open a separate tool to see their NBA recommendations, adoption will be low. The programs that work embed recommendations directly into the CRM interfaces already in use, Veeva, Salesforce, or whatever system the field team operates in daily. The recommendation appears as part of the call plan, not as an additional task with a separate login.
Shift the cadence gradually
Moving from a quarterly POA cycle to a daily or weekly NBA-driven cadence is a significant change in how commercial teams think about strategy and execution. The implementations that work phase this transition. Start with NBA-informed call planning running alongside the existing cycle. Show reps that the recommendations correlate with better outcomes. Build from there. The goal is a field team asking for more NBA input, not one being told to comply with a system they didn’t choose.
Make it part of how performance is reviewed
Field managers who look at NBA performance data in one-to-ones, alongside traditional metrics, create an environment where the tool is taken seriously. That matters more than almost any product feature. Culture (not technology) moves adoption. And clear data can help prove value to reps – at one client, reps using NBA saw 14% higher sales within 9 months of rollout.Â
What this looks like in 2026
The NBA programs performing best right now are not static recommendation engines running on a fixed dataset. They’re learning systems that operate across field, brand, and digital channels at once, updating recommendations as new signals arrive, triggering digital actions automatically where a rep doesn’t need to be involved, and feeding every outcome back into the model.
Powered by the best-in-class Aktana engine, tThe inclusion of Next Best Action capabilities within PharmaForceIQ’s optichannel platform reflects where the industry is heading. NBA is most effective not as a standalone tool but as the intelligence layer inside a broader engagement model, one that deploys resources on the channels that matter most for each HCP, triggered by real signals rather than a predetermined schedule applied across a segment.
For commercial teams asking whether their NBA program is working the way it should, the test is simple: does the system tell your field team and your digital channels what to do next, for each individual HCP, in a way they actually act on? If the answer has qualifications, there is room to improve.
Want to see NBA in action?
Request a demo or read this case study to see how the PharmaForceIQ optichannel platform puts it to work.Â